Yahoo Finance

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed ...
Yahoo Finance

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of ...
Mena FN

Mediwound Announces Positive Results In Head-To-Head Comparison Of Escharex® Vs. SANTYL® Within The Chronex Phase II Randomized Controlled Study

(MENAFN- GlobeNewsWire - Nasdaq) Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and ...
Investing

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx ® vs. SANTYL ® within the ChronEx Phase II Randomized Controlled Study

Results demonstrate superiority of EscharEx ®, a bromelain-based gel vs. SANTYL ®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients ...